New Delhi: The expiry of semaglutide’s key patent in India in March 2026 is ushering in a tsunami of generic versions of the blockbuster diabetes and weight-loss molecule, leading to what industry insiders are calling a “slum of brands.” With the active ingredient behind Wegovy, Ozempic, and Rybelsus facing open competition, more than two dozen Indian pharmaceutical firms are preparing to launch semaglutide-based generics under a bewildering array of names.A Major GLP-1 Franchise Goes Off PatentSemaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk under brand names Ozempic (for type-2 diabetes), Wegovy (for chronic weight management), and Rybelsus (the oral formulation for type-2 diabetes), has dominated the obesity and type-2 diabetes market due to its strong clinical results and high patient demand. In India, patents covering semaglutide’s composition and delivery expired or will expire by March 2026, allowing local drugmakers to enter the highly lucrative “anti-obesity/diabetes” space with their own versions.Also Read: Dr Reddy’s Prepares Generic Semaglutide Entry Under Brand Obeda, Targets 60% Price Cut: ReportAs per a recent Business Standard report, the recent DCGI clearances for generic semaglutide, including approvals for Sun Pharma’s Noveltreat and Sematrinity, signal the first wave of formal regulatory entries ahead of broader launches.Prices for the innovators such as Wegovy and Ozempic are high — often above ₹15,000–₹25,000 per month — prompting both price reductions by original manufacturers and intense market interest from generic players.Also Read: 7 Pharma Firms Eye Generic Semaglutide, Prices May Fall 50% Post Patent Expiry: ReportWhy So Many Brands? A Primer on the ‘Slum of Generics’There are several reasons for the proliferation of branded generics:1. Patent Expiry Unlocks Competition:With semaglutide’s exclusivity eroded, any firm with manufacturing and regulatory capability can produce analogues — leading to a free-for-all in brand naming and product positioning.2. India’s Generics Ecosystem:India is the “pharmacy of the world,” known for low-cost manufacturing and rapid scale-up of generic APIs and formulations. Multiple players are ready to tap into semaglutide demand for both domestic and export markets.3. Massive Market Potential:NDTV reports that Bloomberg analysts estimate the combined obesity and diabetes therapy market could be worth tens of billions globally by the decade’s end; in India alone, semaglutide-class drugs have quickly scaled to hundreds of crores in annual sales.4. Price Sensitivity and Market Share:Indian patients are highly price-sensitive, and branded generics with aggressive pricing can rapidly supplant premium innovator therapies, making the segment highly competitive.Major Semaglutide Generic Brands (India Market Post-Patent)Brand Name Manufacturer/Marketer1. Wegovy NovoNordisk2. Ozempic NovoNordisk3. Ryblsus NovoNordisk4. Poviztra emcure5. Obeda Reddys6. Mashema Zydus Healthcare7. Wyntide Corona8. Semaglip Lloyd9. Semaglide Alkem10. Semanat Natco Pharma11. Semanta Ajanta Pharma12. Samakind Mankind Pharma13. Semastar Torrent Pharmaceuticals14. Semaglut Anthem Biopharma15. Semaglyn Zydus Healthcare16. Sematop Ajanta Pharma17. Semalite Macleods Pharmaceuticals18. Semaday Macleods Pharma19. Semathem Themis Medicare Ltd20. Semapride Micro Labs21. Semastrike Unison Pharma22. Semazit Glenmark Pharma23. Semalup Lupin24. Zepsema Torrent Pharmaceuticals25. Semabig Msn Laboratories26. Semavance Aristo Pharma27. Trusema Torrent Pharmaceuticals28. Semaglura Akums Drugs Pharma29. Semaglu Vida Laboratories Ltd.30. Semalembic Alembic Pharma31. Semadirect Aristo Pharma32. Semaro Alembic Pharma33. Glusema Cue Labs Pharma34. Semavic Alkem Laboratories35. Semaliv Amon Biotech36. Sematide Blisson Medica37. Semafit Ajanta Pharma38. Noveltreat Sun Pharma39. Sematrinity Sun Pharma40. Semaryl Intas Pharmaceuticals41. Zyglutide Hab Pharmaceuticals42. Semgluta Mankind Pharma43. Semaglu Mankind Pharma44. Semglee Mylan Pharmaceuticals45. Seglu Torrent Pharmaceuticals46. Semagla Linux Laboratories47. Semglyn Zydus Healthcare48. Semglide Medicamen Life Sc.49. Semaclu Heet Healthcare50. Diagluton Dr. Reddys Laboratories51. Obesema Alkem Laboratories52. Glp S Alkem Laboratories53. Glp 1 Neo Ethecom Biosciences54. Mesemra Alkem Laboratories55. Semalix Torrent PharmaceuticalsWhat Comes Next: Price Wars and Access ExpansionOnce generics launch, price erosion is expected to be steep — possibly up to 50–80% below current branded costs — making semaglutide therapies far more affordable for both obesity and diabetes patients.Industry watchers anticipate that market dynamics will shift from premium mono-brand dominance to fragmented “branded generics wars,” where multiple manufacturers seek share through pricing, pen delivery innovations, and distribution networks, thereby democratizing access, reports TOI.While cheaper generics could dramatically expand patient access, clinicians warn about appropriate use and medical supervision, especially given widespread interest (and some off-label demand) for obesity indications. Regulatory oversight and physician guidance remain critical.